Almost a week after announcing Baxter was going to break into two divisions, the Illinois company is already expanding.

Crain’s Chicago Business reports that the company is buying up partner Chatham Therapeutics for $70 million.

Crain’s notes that the $70-million deal may not be an all-in-one payment and that Baxter may provide the gene therapy company milestone payments even after the purchase.